Clinical InvestigationElectrophysiologyIncidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension
Section snippets
Patients
In this retrospective single-center study, files from 231 consecutive patients with PAH or inoperable CTEPH treated between 1998 and 2003 were analyzed for episodes of SVTs. All patients were regularly seen at 1 to 6 monthly intervals, or whenever clinically indicated, in the outpatient clinic for PH. Close physical examination and 12-channel electrocardiograms (ECGs) were obtained as part of the regular follow-up program during each individual visit. None of the patients was carrying any
Pulmonary hypertension population
A total number of 231 consecutive patients were included in this study. At the time of inclusion, all patients were in sinus rhythm, except for 2 patients with permanent atrial fibrillation (up to 5 years before the diagnosis of PH). The baseline characteristics of the entire population are shown in Table I.
Incidence of sustained SVT
Thirty-one episodes of sustained SVT were observed in 27 patients, resulting in a cumulative incidence of 11.7% and an annual risk of 2.8% per patient. The average interval between time of
Discussion
The clinical relevance of SVTs has not been systemically studied among patients with PH. The present study shows that SVTs pose a significant threat to this group of patients. In the present cohort of patients with PAH or inoperable CTEPH, the annual incidence of newly onset SVT was approximately 3%, with atrial fibrillation and atrial flutter being the most common types of SVT. The average interval between diagnosis of PH and onset of SVT was 3.5 years, suggesting that these arrhythmias are
References (48)
- et al.
Primary pulmonary hypertension
Lancet
(2003) - et al.
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study
Lancet
(2001) - et al.
Beraprost therapy for pulmonary arterial hypertension
J Am Coll Cardiol
(2003) - et al.
Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study
Chest
(2002) - et al.
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival
J Am Coll Cardiol
(2002) - et al.
Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction
Am J Cardiol
(1986) - et al.
Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies
J Am Coll Cardiol
(1997) - et al.
Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation
J Am Coll Cardiol
(1997) - et al.
Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
Chest
(2004) - et al.
Differentiation of atypical atrioventricular node re-entrant tachycardia from orthodromic reciprocating tachycardia using a septal accessory pathway by the response to ventricular pacing
J Am Coll Cardiol
(2001)
Diagnostic value of tachycardia features and pacing maneuvers during paroxysmal supraventricular tachycardia
J Am Coll Cardiol
Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure
Chest
Primary pulmonary hypertension: a vascular biology and translational research “Work in progress”
Circulation
Pulmonary arterial hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop
Circulation
Cellular and molecular pathobiology of pulmonary arterial hypertension
J Am Coll Cardiol
Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group
Ann Intern Med
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group
N Engl J Med
Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin
Ann Intern Med
Sitaxsentan therapy for pulmonary arterial hypertension
Am J Respir Crit Care Med
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial
Am J Respir Crit Care Med
Bosentan therapy for pulmonary arterial hypertension
N Engl J Med
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial
Ann Intern Med
Survival in patients with primary pulmonary hypertension. Results from a national prospective registry
Ann Intern Med
Survival in primary pulmonary hypertension: the impact of epoprostenol therapy
Circulation
Cited by (209)
Hospital Outcomes in Patients With Pulmonary Hypertension With Atrial Fibrillation in the United States
2024, American Journal of CardiologyAtrial flutter and fibrillation in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension in the ASPIRE registry: Comparison of rate versus rhythm control approaches
2023, International Journal of CardiologyCitation Excerpt :Restoration of sinus rhythm was associated with improvement in ISWD in 78% and in FC in 41% of patients. These data are consistent with previous reports [3–10]. For example, in the study of Olsson et al [7], mean 6-min walk test distance dropped from 362 to 258 m with the onset of arrhythmia and increased back up to 345 m after cardioversion, whilst in Wen et al [8] atrial arrhythmias were associated with clinical worsening in 97.5% of the patients, whilst all of them improved after sinus rhythm was restored.
Pulmonary hypertension
2022, Medicine (Spain)Right heart failure: A narrative review for emergency clinicians
2022, American Journal of Emergency Medicine